Share your videos with the world

Joy is going where the mood takes you. Versatile and functional, the BMW X1 is perfectly engineered for spontaneity. Discover more.

In a new round of evaluations, 5 of 7 small SUVs earn good ratings from the Insurance Institute for Highway Safety for occupant protection in a passenger-side small overlap front crash. The ratings bring to 16 the number of small SUVs the Institute has evaluated in the passenger-side small overlap front test, which was introduced in 2017 to encourage manufacturers to offer the same level of protection for front-seat passengers as drivers in this type of crash. The BMW X1; Chevrolet Equinox and its twin, the GMC Terrain; Jeep Compass and Mitsubishi Outlander earn good ratings in the passenger-side small overlap front test. The Mitsubishi Outlander Sport earns a marginal rating, and the Ford Escape earns poor. For the 2018 model year, the Equinox shed weight to join the small SUV size class. Earlier models were classified as midsize. None of the newly rated 2018 models earns better than acceptable marks for structure. (The Honda CR-V and Mazda CX-5 are the only small SUVs evaluated so far to earn good ratings for structure in the passenger-side small overlap front test.) The Outlander Sport is marginal, and the Escape is rated poor. Both the Outlander Sport and Escape allowed too much intrusion into the occupant compartment on the right side.

Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine. The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection. To view the multimedia release go to: http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/